Delivery Order SPE2DB24D2011-SPE2DB25FBPWJ

Award Date 1/27/25
Potential Completion Date 1/28/25
Potential Value $2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,785.40, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has a completion date of December 31, 2024 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,174.55 and provides for the delivery of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which has a total value of $999,999,999 and runs...
This federal contract award, valued at $2,284.38, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award, valued at $1,299.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has a period of performance ending on April 24, 2025 and is a firm fixed-price arrangement. This award is not associated with a set-aside program. AmerisourceBergen Drug Corp holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $1,263.91 delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medication, with a performance period extending through May 9, 2025. The contract is a firm fixed-price delivery order and is not set-aside. AmerisourceBergen Drug Corporation holds a significant $999,999,999.00 Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a ceiling value of $1,273.95 and a completion date of February 12, 2025. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,312.65 firm fixed price delivery order is for XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,026.84 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML medical products. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,373.11 firm fixed-price delivery order is for the medication XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, with a performance period ending on April 22, 2025. This award is not a set-aside contract. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,018.63, is for the delivery of the pharmaceutical product XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 27, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued...
  • SPE2DB24D2011
    Indefinite Delivery Contract
  • SPE2DB24D2011-SPE2DB25FBPWJ
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,978.72, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML medical supplies. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 4/28/25, 9:42 AM